Phase I/II trial of a low-emetic combination of S-1 plus docetaxel (DTX) for advanced non-small cell lung cancer (NSCLC).


e18041 Background: S-1, a novel oral fluorouracil derivative, is active against NSCLC. Previous studies investigating a combination of S-1 plus DTX showed promising efficacy but clinically problematic emesis. We conducted a phase I study to find the maximum tolerated doses (MTD) of bi-weekly administered DTX with oral S-1 for one week, and a phase II study… (More)